Figure S1



Figure S1. Teniposide induced stronger p-IRF3 and p-P65 expression in human HCC cells in comparison to the commonly used chemotherapy drug.

(**A**) Hep3B and Huh7 cells were treated with sorafenib, doxorubicin, 5-fluorouracil, cisplatin, oxaliplatin or teniposide at serial doubling diluted concentrations for 24 h, then the inhibition rates were determined by a CCK-8 kit, the 50% inhibitory concentration (IC50) values were calculated by graph prism 7. (**B**) Hep3B and Huh7

cells were treated with sorafenib, doxorubicin, 5-fluorouracil, cisplatin, oxaliplatin or teniposide at each IC50 for 24 h, then the cellular protein expression of p-IRF3 and p-P65 was detected by immunoblotting, β-actin was used as a loading control. Data in **(A)** are shown as mean ± SD of 3 independent experiments. Data in **(B)** are representative of 3 independent experiments.